Antibody-Palladium Conjugates for Bioorthogonal Anti-Cancer Prodrug Activation

钯或金等贵金属可以被精细切割植入肿瘤，目的是激活癌变组织内的化疗药物，从而减少其副作用。针对肿瘤表面抗原的抗体的发展作为一种新的靶向策略进行了研究，目的是促进药物在肿瘤部位以受控的方式释放。Unciti-Broceta集团建议使用非生物金属钯来开发抗体-钯偶联物（pd -生物偶联物或pd -免疫偶联物）作为催化癌症靶向抗体，以便通过局部释放临床抗癌药物（前药）来杀死癌细胞/肿瘤。

Precious metals such as palladium or gold can be implanted finely sliced into tumours with the aim of activating chemotherapeutic drugs within the cancerous tissue, thus reducing their side effects. The development of antibodies directed towards tumour surface antigens is investigated as a novel targeted strategy with the aim to promote the release of drugs in a controlled manner exclusively at tumour sites. The Unciti-Broceta Group propose the use of palladium, an abiotic metal, to develop Antibody-Palladium Conjugates (Pd-bioconjugate or Pd-Immunoconjugate) as catalytic cancer targeted antibodies in order to kill cancer cells/tumors by the localised release of clinical anticancer agents (prodrugs).